Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Developmental origins of brain disorders: roles for dopamine

Kelli M. Money, Gregg D. Stanwood

Frontiers in Cellular Neuroscience · 2013 · Review

doi:10.3389/fncel.2013.00260

Abstract

Neurotransmitters and neuromodulators, such as dopamine, participate in a wide range of behavioral and cognitive functions in the adult brain, including movement, cognition, and reward. Dopamine-mediated signaling plays a fundamental neurodevelopmental role in forebrain differentiation and circuit formation. These developmental effects, such as modulation of neuronal migration and dendritic growth, occur before synaptogenesis and demonstrate novel roles for dopaminergic signaling beyond neuromodulation at the synapse. Pharmacologic and genetic disruptions demonstrate that these effects are brain region- and receptor subtype-specific. For example, the striatum and frontal cortex exhibit abnormal neuronal structure and function following prenatal disruption of dopamine receptor signaling. Alterations in these processes are implicated in the pathophysiology of neuropsychiatric disorders, and emerging studies of neurodevelopmental disruptions may shed light on the pathophysiology of abnormal neuronal circuitry in neuropsychiatric disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

INTRODUCTION

Brain development requires a complex interplay of genetic and environmental factors. Disruption of these elements can affect neuronal structure, function, or connectivity and can alter developmental trajectory. In turn, this can lead to long-lasting, even permanent, effects and contribute to brain disorders later in life. Neurodevelopmental alterations in the frontal/prefrontal cortex and striatum, which are both heavily involved in cognition, memory, emotion, and learning, are likely involved in the etiology of neuropsychiatric disorders like autism, substance use disorders, and schizophrenia. These brain regions receive prominent dopamine (DA) innervations and express DA receptors. In fact, DA and other neurotransmitters are expressed even prior to synaptogenesis, and activation of their receptors during development alters brain structure and connectivity with enduring anatomical and behavioral effects through adulthood. However, the cellular and functional consequences of these activities are still poorly understood, and their linkages to specific diseases are often indirect and poorly elucidated.

Here we will review evidence for the role of DA receptors in neurodevelopmental processes with an emphasis on how DA D1 and D2 receptors modulate neuronal morphology in the frontal cortex and striatum. We will then briefly discuss the relevant intracellular signaling mechanisms through which DA receptors modulate neuronal morphology, and conclude with the implications of altered DA signaling on our understanding of the etiology and pathophysiology of neuropsychiatric disorders.

ONTOGENY OF DOPAMINERGIC INNERVATION AND RECEPTOR EXPRESSION PATTERNS

DA innervation and receptor expression are present early in development, mature during adolescence, and form stable patterns in young adulthood. This prolonged developmental timeline provides a large window of “critical periods” during which potential disruptors can induce varied effects. For example, a landmark study by showed that repeated exposure to methylphenidate (Ritalin) during the juvenile period reduces cocaine reward in adulthood, whereas adult methylphenidate exposure does not confer this protection.

Alterations in DA innervation patterns and receptor expression have been found in several brain disorders, including psychiatric disease. A decrease in DAergic axons in deep layers of medial prefrontal cortex and decreased D1 receptor binding occurs in schizophrenic patients. In addition, increased D2 receptor binding in the striatum has been observed in patients with ADHD and depression. An understanding of the developmental timeline of the DA system and points at which the normal developmental trajectory can be altered are crucial to explore the implications of DAergic disruption.

The frontal cortex and striatum are innervated by DA-containing axons from the mesencephalic DA nuclei by mid-to-late gestation in rodents, the predominant animal models used to study the developmental roles of DA. demonstrated that DA innervation develops in well-defined spatiotemporal gradients in the lateral ganglionic eminence (presumptive striatum) that begins by embryonic day (E) 14 and coincides with striatal neurogenesis and cell differentiation. The rat developing cortex receives DAergic fibers that pass through the striatum, with innervation occurring in a lateral (E16) to medial fashion (E19). At birth, DAergic fibers are concentrated in the developing layer VI of frontal cortex. Fiber density increases over time in the deep layers of cortex with some fibers innervating more superficial layers in discrete cortical regions as the more superficial cortical layers develop. Mature DAergic innervation patterns are established in both regions by postnatal day 60. Studies in other species suggest that these sequences of events are very well conserved evolutionarily, although the exact timings are of course quite different based on gestation length (see below).

Dopamine receptor expression develops in concert with DAergic innervation. DA receptors are part of the G-protein coupled receptor superfamily and can be classified into two subgroups based on sequence, pharmacology, and G protein signaling: D1-like, which includes D1 and D5 receptors, and D2-like, which includes D2, D3, and D4 receptors. Even before DAergic afferents have fully occupied the striatum or cortex, the main two DA receptor subtypes (D1 and D2 receptors) are already present. Higher levels of expression for both subtypes are found in the striatum compared to frontal cortex from development to adulthood, and the D1 receptor subtype is expressed at higher levels than the D2 receptor subtype in both regions. D3, D4, and D5 receptors are consistently expressed at lower levels but still are present even during prenatal development. For example, D3 and D5 receptor mRNA is first found in the striatum at E12 and frontal cortex by E15. However, D4 receptor mRNA, which is also present in the striatum at E12 and frontal cortex by E15, has its highest expression during embryonic development. D4 receptor mRNA decreases after birth with a more significant drop in expression seen in the frontal cortex. D3 receptors are also are expressed transiently within the early postnatal somatosensory cortex during a key critical period of plasticity, although their function there remains unknown.

Dopaminergic development continues postnatally and impacts forebrain synaptogenesis and connectivity. For example, D1 receptor pruning is specifically associated with maturation of the excitation-inhibition balance in frontal cortex during adolescence. demonstrated that D1 receptor expression steadily declines after the fourth postnatal week, which has been confirmed by others and is illustrated in Figure 1C. Cortical circuits and processing relies on connectivity and excitability of both excitatory glutamatergic pyramidal neurons and inhibitory GABAergic interneurons. Disruptions of excitation-inhibition balance in the frontal cortex have been reported in patients with schizophrenia, autism, major depressive disorder, and obsessive compulsive disorder, and many of these patients present with a first episode around adolescence. Risk of substance abuse disorders also increases during adolescence. Genetically mediated DA variability has been suggested to shape complex behaviors emerging in adolescence, such as impulsivity and sensation seeking. DAergic regulation of frontal cortex output to subcortical areas mediates drug seeking behavior, with D1 receptor activation enhancing cortically driven drug seeking. Moreover, cortical output neurons to the nucleus accumbens, a subcortical reward area, express higher levels of D1 receptors during adolescence in rodent models. This correlates with increased sensitivity to cocaine conditioned place preference. found this increased preference to be enhanced with microinjections of D1-like receptor agonist in the prefrontal cortex but blunted with D1-like receptor antagonist, demonstrating the importance of D1 receptor signaling in heightened adolescent sensitivity to cocaine preference. This work demonstrates how the prolonged development of the DA system allows for vulnerability into adolescence. Thus, inappropriate alterations in D1 receptor signaling during adolescent cortical maturation could play a significant role in the development of neuropsychiatric diseases.

Phylogenetic differences in brain development exist between rodents and higher mammals. In regards to DA, monkeys and humans have more widespread cortical DA input than rodents and significantly denser DAergic innervation in motor, premotor, and supplementary motor association cortices. Human DAergic innervation occurs early in development and is strongly established by mid-gestation. The density of DAergic fibers to the prefrontal cortex in non-human primates increases during preadolescence, peaks during adolescence, and then declines. This evolution of the cortical DAergic system in primates suggests a more substantial role for DAergic innervation in development in more evolved species. The increased influence of DA in the human brain is exemplified by the increase in neuropsychiatric disease onset during adolescence, the time period when the DA system matures. The role of DA system development in neuropsychiatric disease vulnerability is an active area of research, and hopefully, the field will soon understand how to correct aberrant DA development in these vulnerable individuals.

STRIATAL AND CORTICAL DOPAMINERGIC PATHWAYS

The striatum receives DAergic innervation from the substantia nigra pars compacta, which is known as the nigrostriatal pathway (shown in Figure 2). These DAergic afferents synapse on two distinct populations of GABAergic projection neurons, which express either D1 or D2 receptors (demonstrated in Figure 1D;;; ). These populations send projections directly to or indirectly through the globus pallidus (external globus pallidus in primates) to the substantia nigra pars reticulata and endopeduncular nucleus (internal globus pallidus in primates) to make up the direct (D1 receptor expressing neurons) and indirect (D2 receptor expressing neurons) pathways to modulate movement and goal-oriented behavior. Dysfunction within these pathways is a hallmark feature of multiple movement disorders, such as Parkinsonism and Huntingdon’s disease. Medications that target DA receptors can also modulate these pathways. For example, typical antipsychotics modulate this system by blocking D2 receptors; this action treats positive symptoms but can also lead to tardive dyskinesia, a serious side effect characterized by involuntary, repetitive movements. The importance of the nigrostriatal DAergic projections onto the direct and indirect pathway projection neurons is made evident by the devastating symptoms that result from disruption of this pathway, but other DAergic pathways can also play an important role in disease.

The ventral tegmental area (VTA), another mesencephalic nucleus, gives rise to two additional DAergic pathways. Projections from the VTA to limbic areas, such as the nucleus accumbens, and to the frontal cortex form the mesolimbic and mesocortical pathways (shown in Figure 2), respectively. In the nucleus accumbens, patterns of D1 and D2 receptor expression are similar to the dorsal striatum (demonstrated in Figure 1D). In addition, the shell of the nucleus accumbens expresses high levels of D3 receptors. DA receptor expression is lower in the frontal cortex and found in several types of neurons. In the frontal cortex, D1 receptors appear to be the most prominent DA receptor, and both D1 and D2 receptors are found in deep layer V/VI glutamatergic projection neurons and parvalbumin-containing GABAergic interneurons. D4 and D5 receptors are expressed at low levels in frontal cortex. Importantly, these pathways and DA receptor expression patterns have great functional significance. The mesolimbic pathway is mainly associated with reward, while the mesocortical pathway is associated with cognitive function. Aberrant reward processing drives substance abuse disorders, and cognitive dysfunction exists as an often overlooked but devastating feature of many neuropsychiatric disorders. Studies of imbalanced mesolimbic and mesocortical DAergic signaling support a potential therapeutic role for DA in reward and cognitive dysfunction in neuropsychiatric disease. Thus, DA can influence multiple aspects of human behavior both directly through striatal projections and indirectly through alterations in reward and cognition (for description of the trajectories of growing DA axons and signals contributing to topography, see ).

DEVELOPMENTAL EFFECTS OF DOPAMINERGIC MODULATION

DA is one of the earliest neurotransmitters expressed in the developing brain and plays a significant role in the development of neuronal cytoarchitecture. The presence of DAergic projections to the developing cortex and striatum, as well as DA receptors on precursor cells, places DA in an ideal position to modulate neuronal development, including cell proliferation, migration, and differentiation all of which can lead to altered connectivity and dysfunctional synapses. In fact, genetic and pharmacologic models of disrupted DA signaling display changes in cortical and striatal circuitry. Environmental, social, and inflammatory challenges during sensitive periods of forebrain development also produce neuro(mal)adaptions in these regions and phenocopy some aspects of brain disorders. For example, models of prenatal infection, stress, and exposure to drugs of abuse show long-lasting changes in DA receptor expression and function and have been associated with increased risk for psychiatric disorders. Taken together, these data have led our group and others to hypothesize that DAergic modulation of developmental processes produces long lasting alterations that contribute to cortical and striatal dysfunction in neuropsychiatric disorders.

NEUROPROGENITOR PROLIFERATION

The earliest observed developmental effects of altered DA signaling are changes in neuroprogenitor proliferation. Selective D1-like receptor agonists can decrease incorporation of the cell cycle marker bromodeoxyuridine (BrdU) in the developing medial frontal cortex and lateral ganglionic eminence, a basal forebrain progenitor pool that is the source for most striatal neurons (illustrated in Figure 1A). Decreased BrdU incorporation is indicative of less neuronal progenitors undergoing division. Both D1-like and D2-like receptors contribute to neurogenesis but with opposite effects; blockade of D1-like receptors and activation of D2-like receptors increase the number of neuronal progenitors undergoing cell division. Administration of the DA precursor L-DOPA during early gestation decreases cell proliferation, suggesting that D1 receptor mediated effects may dominate in vivo. Although these studies did not mechanistically investigate how D1 and D2 receptors alter BrdU incorporation, another group examined receptor-induced changes in cell cycle protein expression. Indeed, D1-like receptor activation promotes downregulation of cyclin D and upregulation of the cyclin dependent kinase inhibitor p27Kip1. Cyclin D promotes the transition from the growth phase to S-phase of the cell cycle while p27Kip1 inhibits it. In addition, Raf-1, a component of the mitogen-activated protein kinase (MAPK) pathway that promotes mitosis, is downregulated by D1-like receptor activation. The mechanism by which these effects on cell cycle proteins occur is not known, although it appears to be PKA-independent. The effects of transient differences in cell cycle proteins have yet to be understood, but small deviations in the number of cells available to release or receive important developmental signals could significantly alter developmental trajectory. And although it is beyond the scope of our current review, it is also worth noting that both acute and chronic DA depletion decreases subependymal neuronal proliferation, and DA receptors, especially D3 receptors, can guide adult neurogenesis as well.

MIGRATION

As mentioned above, inappropriate excitation-inhibition balance in frontal cortex is found in several neuropsychiatric diseases, which could be partly due to a lack of adequate interneuron migration. The two main cell types in the frontal cortex, glutamatergic pyramidal projection neurons and GABAergic interneurons, are derived from two separate progenitor pools in the developing rodent forebrain. Pyramidal neurons are produced locally in the neuroepithelium of the developing cortex and migrate radially to the appropriate cortical layer. Concurrently, GABAergic interneurons generated in the basal forebrain in the medial and caudal ganglionic eminences migrate tangentially to the cortex. The number of GABAergic interneurons increases through mammalian brain evolution beyond what the ganglionic eminences can provide. Therefore, in primates, GABAergic interneurons are also produced in the dorsal forebrain and migrate radially through cortex. However, this tangentially migrating population of interneurons is still a substantial portion of interneurons produced, and dysregulation of either population would contribute to neuropsychiatric disease.

GABAergic neurons in the medial and caudal ganglionic eminences express DA receptors, and these forebrain regions receive DAergic innervation during the embryonic period when migration occurs. The Bhide lab has demonstrated that altering DA receptor signaling with prenatal cocaine or receptor-specific agonists/antagonists disrupts tangential migration (illustrated in Figure 1A). Prenatal cocaine exposure decreases tangential migration of cortical GABAergic neurons, perhaps mediated by the loss of D1 receptor signaling. In addition, application of D1-like receptor agonists in mouse embryonic slice cultures promotes cortical GABAergic neuron migration whereas D2-like receptor agonism decreases migration. Overexpression of the D1 receptor by in vitro electroporation increases the effect of D1-like receptor agonists on promoting tangential migration. The basis for opposing D1 vs. D2 receptor effects is not fully understood, but cytoskeletal reorganization must occur for neuronal migration. D1-like receptor stimulation leads to increased neurite localization of cytoskeletal elements needed for cell motility, such as cytoplasmic dynein motor protein and tubulin, whereas D2-like receptor stimulation leads to increased cell body localization of these cytoskeletal elements. suggest that this subtype-specific redistribution of cytoskeletal elements needed for cell motility leads to opposite effects on neuronal migration. Elucidation of the molecular pathways responsible for receptor-dependent modulation of neuronal migration may provide new targets for the restoration of neurodevelopmental trajectory.

DENDRITIC AND AXONAL GROWTH

Dendritic and axonal growth are activity-dependent, highly dynamic processes that remain partially plastic until adulthood. Disruption of dendritic or axonal growth alters both the quantity and nature of neural connections. Not surprisingly, anomalies in brain connectivity have been linked to several neuropsychiatric diseases, including intellectual disability and schizophrenia. In fact, DA receptor activation modulates dendritic structure, creating subtle but significant changes in brain architecture that may increase vulnerability to neurological and/or neuropsychiatric disease.

In this regard, activation of DA receptors influences axonal and dendritic growth in a subtype-specific manner. Primary cultures have been the primary model to test the in vitro effects of DAergic modulation on neurite outgrowth, a term to describe both the developing axon and dendrite. Several groups demonstrated that D1-like receptor agonists significantly reduce neurite outgrowth in frontal cortical neuronal cultures, which is depicted in Figure 1B. further observed that decreased neurite outgrowth is associated with destabilization of dendritic microtubule associated protein (MAP2) by increased phosphorylation. Increased MAP2 phosphorylation is commonly associated with decreased neurite outgrowth. However, activation of numerous kinases causes MAP2 phosphorylation, providing an effector but not the mechanism. An animal model of prenatal cocaine exposure also demonstrates the importance of cortical D1 receptor signaling to suppress neurite outgrowth. This model produces a long-lasting uncoupling of D1 receptor signaling and concomitant increase in neurite outgrowth. Our group has also observed increased basal neurite outgrowth in cortical cultures derived from D1 receptor null embryos as compared to cultures derived from wild-type littermates (unpublished data). With regards to axonal effects, evidence suggests that D1-like receptor stimulation also alters cortical axon growth patterns by decreasing expression of the netrin-1 receptor. In contrast to the growth-suppressing effects of D1-like receptor stimulation, D2-like receptor activation in primary cortical cultures leads to an increase in neurite outgrowth (illustrated in Figure 1B;; ). Thus, D1-like receptor stimulation decreases neurite outgrowth and netrin-1 receptor expression whereas D2-like receptor stimulation increases neurite outgrowth in vitro. Yet, the DA receptor-expressing population is only approximately 10–15% of neurons in the frontal cortex. Ongoing research in our group is testing whether these effects are cell-specific (only occurring in neurons expressing DA receptors) or if a non-cell specific mechanism leads to DA receptor-induced changes on neurite outgrowth in other subpopulations.

In contrast, application of D1-like receptor agonists to striatal neuronal cultures promotes neurite outgrowth, which can be blocked with D1-like receptor antagonists and is demonstrated in Figure 1B. This increased neurite outgrowth is associated with an increased number of growth cones and arborization. However, D2-like receptor activation shows no effect on striatal neurite outgrowth (also demonstrated in Figure 1B; ). Hence, D1-like receptor stimulation increases neurite outgrowth in the striatum in vitro.

Studies from intact brains bolster the importance of developmental DA receptor signaling on dendritic growth in DA-rich brain regions. Models of DA depletion (i.e., 6-OHDA treatment or mesencephalic lesion) show decreased expression of axon guidance- and cytoskeletal growth-related proteins as well as decreased length of pyramidal layer V basal dendrites in frontal cortex. In human studies, adolescents exposed prenatally to cocaine display changes in cortical thickness. MAP2 labeling of D1 receptor knockout mice and diolistic labeling of rabbits prenatally exposed to cocaine show abnormal apical dendrites of cortical pyramidal cells with decreased bundling and increased tortuous patterning, which supports the increased basal neurite outgrowth observed in vitro. Conversely, silver impregnation of cortical neurons from D1 receptor overexpressing mice show decreased apical dendrite length compared to wild type littermates, which further supports a role for D1 receptor signaling to promote dendritic growth. Finally, the Kellendonk lab has shown that mice overexpressing D2 receptors in the striatum have decreased complexity and length of striatal dendritic arbors. Although differences in normal striatal dendritic morphology have been studied based on receptor subtype expression, to our knowledge the effects of reduced or absent D1 receptor signaling on striatal dendritic morphology has not been examined.

SPINOGENESIS AND SYNAPTOGENESIS

Dendritic spinous processes start to form at the beginning of synaptogenesis during the first postnatal week and peak in adolescence but continue to be structurally modified throughout adulthood. Spines develop from dendritic filopodia that interact with incoming axons, but some data suggest that dendritic spines can form independent of axonal interaction. Dendritic spines are critical for synaptic plasticity, allowing for compartmentalization of post-synaptic signaling and synaptic specialization. Additionally, alterations in spine density likely originating during development are found in many neuropsychiatric diseases, such as autism and schizophrenia. Importantly, DA plays a role in spinogenesis. For example, a functional hyperdopaminergia, which occurs in DA transporter (DAT) knockout mice, leads to a loss of proximal dendritic spines in striatal projection neurons. This model also shows a behavioral phenotype of hyperactivity and anxiety as well as altered mesocortical circuitry, and DA dysregulation occurs not only during development, but continues into adulthood in this model. Primate and rodent models of DA depletion also show decreases in striatal dendritic spines. Thus, a delicate balance of DA signaling is required for formation/stabilization of dendritic spines. Cortical pyramidal neurons of D1 and D2 receptor knockout mice exhibit decreased dendritic spine density, and moderate D1-like and D2-like receptor activation both have been shown to increase spine density and spinophillin expression in the striatum in vitro. Studies have not yet shown if higher concentrations of DAergic agonists, more like the activation levels seen in the hyperdopaminergic DAT knockout mouse, would phenocopy the decreased dendritic spine density seen in that (potentially non-physiological) mutant. In fact, during adolescence D2 receptor activation decreases striatal dendritic spines. Interestingly, the spine loss in cortical pyramidal neurons resulting from DA depletion can be ameliorated by spinogenesis-promoting antipsychotics like clozapine, providing further support for spine dysfunction in the pathology of neuropsychiatric disease.

Since dendritic spines serve as the recipients of synaptic input and both develop concurrently, spinogenesis and synaptogenesis are intimately connected and are often co-regulated. Multiple points of vulnerability beyond spine formation can be altered to disrupt synaptogenesis. Axonal pathfinding must lead to the vicinity of the target neuron for initial contact to be made. Cell-cell adhesion then needs to occur, followed by pre- and post-synaptic differentiation and synapse strengthening. Synapse formation, when it occurs properly, leads to the formation of connections on a particular part (usually dendritic spines) of a target neuron, sometimes over very long distances. Schizophrenia and other neurodevelopmental disorders are at least in part, diseases of altered synaptic connectivity. Inappropriate dendritic arborization, spinogenesis, and synaptic connections lead to inappropriate connectivity and altered excitation-inhibition balance. This is supported by observations of decreased dendritic spines and synaptic labeling in post mortem cortex of schizophrenic patients. Thus, synaptogenesis can be altered by any of the previously discussed developmental events and plays an important role in neuropsychiatric disease pathology.

Synaptogenesis follows a similar timeline of development as spinogenesis and displays similar responses to DAergic modulation. Synapses begin to form during the first postnatal week. The number of synapses peak during adolescence, which is followed by synaptic pruning. In the striatum and frontal cortex, electron microscopy has shown that DAergic axons form symmetric synapses similar to most GABAergic interneurons whereas glutamatergic pyramidal axons forms asymmetric synapses. Neonatal DA depletion decreases the number of symmetric synapses and changes the structure of asymmetric synapses. Others have suggested that neonatal DA depletion can alter dendritic structures in the frontal cortex, and cause dysregulation of gene expression patterns required for normal brain architecture. DA receptor antagonists can decrease prefrontal synapse density whereas agonists slightly increased density. Furthermore, haloperidol, a D2-like receptor antagonist, decreases hippocampal synaptic density in vitro. Opposing D1 vs. D2 receptor developmental effects are lost with regards to spinogenesis and synaptogenesis, and hopefully further study will produce a mechanistic explanation. DA lesion studies in adult animals support a continued role for DA in the maintenance of corticostriatal synapses in the striatum (for a comprehensive review of DA-regulated morphological and electrophysiological changes, please see and ). Taken together, these studies support a crucial role for DA in formation and stabilization of synaptic connections in the striatum and frontal cortex, providing further evidence for developmental disruptions of DA and other neurotransmitters in the structural pathology of neuropsychiatric disease.

DOPAMINE D1 RECEPTOR SIGNALING MECHANISMS IN DEVELOPMENTAL PROCESSES

Establishing a detailed signaling mechanism for the above mentioned in vitro and in vivo effects on developmental processes is complicated by multiple signaling cascades and receptor interactions. While all five DA receptors likely contribute to these effects in specific ways, studies to date have predominantly examined D1 receptors, and thus our discussion will also focus there. In general, D1-like receptors transduce their signals by activating adenylyl cyclase and increasing intracellular cAMP via Gαs/Gαolf coupled proteins. Conversely, D2-like receptors typically transduce their signals by inhibiting adenylyl cyclase and decreasing cAMP. Intracellular cAMP activates protein kinase A (PKA), which phosphorylates proteins such as DA and cAMP-regulated phosphoprotein (DARPP-32) and cAMP responsive-element binding protein (CREB;; ). CREB promotes transcription of genes with cAMP response elements. Additionally, MAPKs like extracellular signal-related kinase (ERK) are activated by D1 receptor stimulation and increase CREB signaling.

DA receptors also participate in multiple non-Gα protein signaling mechanisms. DA receptor mediated effects can involve Gβ/Gγ proteins as well as other receptors. For example, D1 receptors interact with NMDA receptors, adenosine receptors, and neurotrophin TrkB receptors, among others. D2 receptors complex with adenosine A2A receptors and sigma-1 receptors and recruit protein kinase B/glycogen synthase kinase 3 (AKT/GSK3) signaling pathways via a slower, cAMP-independent signaling mechanism. G protein-coupled receptor kinases and arrestins, normally associated with receptor desensitization, form a scaffold for D2 receptor interactions with protein phosphatase 2A and AKT. The resulting dephosphorylation of AKT increases activity of GSK3, a target of lithium and many antipsychotic drugs.

Given the profound differences between how neurites of cortical and striatal neurons respond to DA receptor agonists, it is likely that intracellular signals are regulated in cell-specific ways. These are difficult experiments to carry out, however, and we currently have a fairly superficial understanding of these mechanisms. Both D1-like receptor agonists and PKA activators increase cortical MAP2 phosphorylation, decreasing the ability of MAP2 to stabilize the dendritic cytoskeleton and thus decreasing neurite outgrowth. Neurite outgrowth facilitation by D1-like receptor stimulation in the striatum is also PKA-dependent and at least in part CREB-mediated. Additionally, the Chao lab has demonstrated that increased neurite outgrowth in striatal cultures is at least partially dependent on D1 receptor-mediated neurotrophin TrkB receptor activation. Their study showed that D1-like receptor agonist treatment in primary striatal cultures leads to activation and increased surface expression of the TrkB receptor, and is accompanied by phosphorylation of downstream Trk signaling proteins. Thus, taken together, current evidence suggests that the D1-like receptor-mediated changes in neurite outgrowth are PKA-dependent in both cortex and striatum with an additional neurotrophin TrkB receptor-dependent component only in the striatum. The dichotomy between D1 and D2 receptor signaling in the context of developmental dysfunction needs to be understood in order to target the neurodevelopmental origins of neuropsychiatric disease. Furthermore, future studies should identify potential roles for differences in G protein coupling (e.g., Gαs in cortex and Gαolf in striatum; ), and accessory proteins with differential expression patterns (e.g., GPR88 in striatum;; ).

GENETIC DISRUPTIONS OF DA SIGNALING AND NEUROPSYCHIATRIC DISEASE

The DA system plays a fundamental role in psychotic disorders, with D2 receptor antagonism being a major target for both typical and atypical antipsychotics. While D2 receptor antagonism may be useful in controlling many of the positive symptoms in schizophrenia, emerging data implicates D1-like receptors as a target for negative symptoms in schizophrenia. In addition, several genetic perturbations in DA-related genes have been found in patients with neuropsychiatric disease. Patients with 22q11 deletion syndrome, which disrupts DA-related genes (e.g., catechol-O-methyltransferase, COMT) among others have an increased risk for neuropsychiatric disorders, including schizophrenia-like psychosis, autism, and anxiety disorders. Hypomethylation of the COMT gene, which leads to an increase in the enzyme that breaks down DA, has been associated with schizophrenia and bipolar disorder. The translocation in the gene disrupted in schizophrenia-1 (DISC-1) was originally found in a large Scottish family with abnormally high rates of neuropsychiatric disease. Interestingly, knockdown of DISC-1 in animal models causes altered DAergic maturation and behavioral changes associated with altered prefrontal cortex circuitry, suggesting a role for DA in DISC-1 associated neuropsychiatric disease. Association studies implicate the A1 allele of the Taq1 polymorphism of DRD2 in the development of Tourette’s syndrome, ADHD, autism, PTSD, and alcoholism. The Holden lab has found DA-related genes (DRD1, DRD2, and PPP1R1B) associated with the severity of autism in families with males only affected. Others have found polymorphisms in DRD3 and DRD4 associated with autism severity and DAT polymorphisms linked to both ADHD and bipolar disorder. Additionally, polymorphisms in the gene encoding the downstream signaling protein Akt are associated with both bipolar disorder and schizophrenia. While the effect sizes in these studies are not large, and the link to DA is sometimes indirect, taken together these findings emphasize that disrupted DAergic homeostasis may be a central mechanism in the risk of developing a neuropsychiatric disorder.

CONCLUSION

There is strong evidence that DA plays a critical role in the generation of typical brain structure and function. DA and its cognate receptors are present in the striatum and frontal cortex early in brain development and contribute to the development of pathways needed for movement, cognition, and reward. Altered DA signaling can affect the proliferation, migration, and differentiation of specific subpopulations of neurons, and thus impact frontal cortex and striatal neurocircuitry. D1 and D2 receptor subtypes often have opposing effects on these developmental processes, and the underlying mechanism for this dichotomy as well as the signaling pathways that mediate these subtype-specific effects remain mostly unknown.

Yet, DA is not the only neuromodulator that plays a role in developmental processes. Serotonin is present before synaptogenesis and alters neurite outgrowth and axon pathfinding in vitro in a receptor-dependent manner (;;;;;;; for comprehensive review of roles of serotonin in development, see;;; ). In addition, decreased cortical thickness in reelin mutants is postulated to be driven by cortical cholinergic deprivation, and both nicotinic and muscarinic cholinergic receptor manipulation alters neurite outgrowth (;;; for comprehensive review, see;; ). Finally, noradrenergic neurons are thought form early synapses in the cortical plate and mediate neuronal migration and laminar formation. DA thus does not provide a singular role in these developmental processes, and future studies will need to address additional neuromodulators in combinatorial patterns.

Our understanding of the role of developmental disruptions of DA in the pathology of neuropsychiatric disorders is still maturing. DA-rich areas, such as the prefrontal cortex and striatum, are clearly dysfunctional in neuropsychiatric disorders like schizophrenia, substance use disorders, and ADHD. Developmental alterations in dendritic growth and/or GABAergic interneuron migration likely contribute to the development of pathology in these disorders. The increased DAergic influence in the cortex of primates and dysfunction of DA-rich cortical areas in neuropsychiatric disorders suggests an evolutionally increased role of DA, which has also resulted in an evolutionarily increased vulnerability to disease. A new era of neuropsychiatric pharmacologic targets should address the underlying pathology resulting from developmental disruptions in DA and other neurotransmitters. Importantly, early interventions have the most positive impacts in neurodevelopmental disorders and learning disabilities; our hope is that a detailed mechanistic understanding of brain substrates and developmental pharmacology will allow clinicians to make similar rational interventions within neuropsychiatry.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 225

  1. 1.

    Abdolmaleky H. M. Cheng K. H. Faraone S. V. Wilcox M. Glatt S. J. Gao F. (2006 ). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum. Mol. Genet. 15 3132–3145

    Not in our library10.1093/hmg/ddl253

  2. 2.

    Ade K. K. Wan Y. Chen M. Gloss B. Calakos N. (2011 ). A improved BAC transgenic fluorescent reporter line for sensitive and specific identification of striatonigral medium spiny neurons. Front. Syst. Neurosci. 5:32

    Not in our library10.3389/fnsys.2011.00032

  3. 3.

    Akil M. Pierri J. N. Whitehead R. E. Edgar C. L. Mohila C. Sampson A. R. (1999 ). Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am. J. Psychiatry 156 1580–1589

    Not in our library10.1176/ajp.156.10.1580

  4. 4.

    Alonso S. J. Navarro E. Rodriguez M. (1994 ). Permanent dopaminergic alterations in the n. accumbens after prenatal stress. Pharmacol. Biochem. Behav. 49 353–358

    Not in our library10.1016/0091-3057(94)90433-2

  5. 5.

    Andersen S. L. Arvanitogiannis A. Pliakas A. M. Leblanc C. Carlezon W. A. Jr (2002 ). Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5 13–14

    Not in our library10.1038/nn777

  6. 6.

    Andersen S. L. Teicher M. H. (2009 ). Desperately driven and no brakes: developmental stress exposure and subsequent risk for substance abuse. Neurosci. Biobehav. Rev. 33 516–524

    Not in our library10.1016/j.neubiorev.2008.09.009

  7. 7.

    Andersen S. L. Thompson A. T. Rutstein M. Hostetter J. C. Teicher M. H. (2000 ). Dopamine receptor pruning in prefrontal cortex during the periadolescent period in rats. Synapse 37 167–169

    Not in our library10.1002/1098-2396(200008)37:2<167::aid-syn11>3.0.co;2-b

  8. 8.

    Anelli T. Cardarelli S. Ori M. Nardi I. Biagioni S. Poiana G. (2013 ). 5-Hydroxytryptamine 1A and 2B serotonin receptors in neurite outgrowth: involvement of early growth response protein 1. Dev. Neurosci. [Epub ahead of print]

    Not in our library10.1159/000354423

  9. 9.

    Antonopoulos J. Dori I. Dinopoulos A. Chiotelli M. Parnavelas J. G. (2002 ). Postnatal development of the dopaminergic system of the striatum in the rat. Neuroscience 110 245–256

    Not in our library10.1016/s0306-4522(01)00575-9

  10. 10.

    Araki K. Y. Sims J. R. Bhide P. G. (2007 ). Dopamine receptor mRNA and protein expression in the mouse corpus striatum and cerebral cortex during pre- and postnatal development. Brain Res. 1156 31–45

    Not in our library10.1016/j.brainres.2007.04.043

  11. 11.

    Arbuthnott G. W. Ingham C. A. Wickens J. R. (2000 ). Dopamine and synaptic plasticity in the neostriatum. J. Anat. 196 (Pt 4) 587–596

    Not in our library10.1046/j.1469-7580.2000.19640587.x

  12. 12.

    Arnsten A. F. (2006 ). Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J. Clin. Psychiatry 67(Suppl. 8) 7–12

    Not in our library

  13. 13.

    Arnsten A. F. (2011 ). Prefrontal cortical network connections: key site of vulnerability in stress and schizophrenia. Int. J. Dev. Neurosci. 29 215–223

    Not in our library10.1016/j.ijdevneu.2011.02.006

  14. 14.

    Arnsten A. F. (2013 ). The neurobiology of thought: the groundbreaking discoveries of Patricia Goldman-Rakic 1937–2003. Cereb. Cortex 23 2269–2281

    Not in our library10.1093/cercor/bht195

  15. 15.

    Arnsten A. F. Wang M. J. Paspalas C. D. (2012 ). Neuromodulation of thought: flexibilities and vulnerabilities in prefrontal cortical network synapses. Neuron 76 223–239

    Not in our library10.1016/j.neuron.2012.08.038

  16. 16.

    Beasley C. L. Reynolds G. P. (1997 ). Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr. Res. 24 349–355

    Not in our library10.1016/s0920-9964(96)00122-3

  17. 17.

    Beaulieu J. M. Gainetdinov R. R. (2011 ). The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol. Rev. 63 182–217

    Not in our library10.1124/pr.110.002642

  18. 18.

    Beaulieu J. M. Gainetdinov R. R. Caron M. G. (2007 ). The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 28 166–172

    Not in our library10.1016/j.tips.2007.02.006

  19. 19.

    Beaulieu J. M. Sotnikova T. D. Marion S. Lefkowitz R. J. Gainetdinov R. R. Caron M. G. (2005 ). An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122 261–273

    Not in our library10.1016/j.cell.2005.05.012

  20. 20.

    Beaulieu J. M. Sotnikova T. D. Yao W. D. Kockeritz L. Woodgett J. R. Gainetdinov R. R. (2004 ). Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 5099–5104

    Not in our library10.1073/pnas.0307921101

  21. 21.

    Bellone C. Mameli M. Luscher C. (2011 ). In Utero exposure to cocaine delays postnatal synaptic maturation of glutamatergic transmission in the VTA. Nat. Neurosci. 14 1439–1446

    Not in our library10.1038/nn.2930

  22. 22.

    Ben-Ari Y. (2013 ). Neuropaediatric and neuroarchaeology: understanding development to correct brain disorders. Acta Paediatr. 102 331–334

    Not in our library10.1111/apa.12161

  23. 23.

    Berger B. Gaspar P. Verney C. (1991 ). Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 14 21–27

    Not in our library10.1016/0166-2236(91)90179-x

  24. 24.

    Berger B. Trottier S. Verney C. Gaspar P. Alvarez C. (1988 ). Regional and laminar distribution of the dopamine and serotonin innervation in the macaque cerebral cortex: a radioautographic study. J. Comp. Neurol. 273 99–119

    Not in our library10.1002/cne.902730109

  25. 25.

    Berger M. A. Barros V. G. Sarchi M. I. Tarazi F. I. Antonelli M. C. (2002 ). Long-term effects of prenatal stress on dopamine and glutamate receptors in adult rat brain. Neurochem. Res. 27 1525–1533

    Not in our library10.1023/a:1021656607278

  26. 26.

    Berlanga M. L. Price D. L. Phung B. S. Giuly R. Terada M. Yamada N. (2011 ). Multiscale imaging characterization of dopamine transporter knockout mice reveals regional alterations in spine density of medium spiny neurons. Brain Res. 1390 41–49

    Not in our library10.1016/j.brainres.2011.03.044

  27. 27.

    Bhide P. G. (2009 ). Dopamine, cocaine and the development of cerebral cortical cytoarchitecture: a review of current concepts. Semin. Cell Dev. Biol. 20 395–402

    Not in our library10.1016/j.semcdb.2009.01.006

  28. 28.

    Bjorklund A. Dunnett S. B. (2007 ). Dopamine neuron systems in the brain: an update. Trends Neurosci. 30 194–202

    Not in our library10.1016/j.tins.2007.03.006

  29. 29.

    Black J. E. Kodish I. M. Grossman A. W. Klintsova A. Y. Orlovskaya D. Vostrikov V. (2004 ). Pathology of layer V pyramidal neurons in the prefrontal cortex of patients with schizophrenia. Am. J. Psychiatry 161 742–744

    Not in our library10.1176/appi.ajp.161.4.742

  30. 30.

    Bonnin A. Levitt P. (2011 ). Fetal, maternal, and placental sources of serotonin and new implications for developmental programming of the brain. Neuroscience 197 1–7

    Not in our library10.1016/j.neuroscience.2011.10.005

  31. 31.

    Bonnin A. Torii M. Wang L. Rakic P. Levitt P. (2007 ). Serotonin modulates the response of embryonic thalamocortical axons to netrin-1. Nat. Neurosci. 10 588–597

    Not in our library10.1038/nn1896

  32. 32.

    Bosboom J. L. W. Stoffers D. Wolters E. C. (2004 ). Cognitive dysfunction and dementia in Parkinson’s disease. J. Neural Transm. 111 1303–1315

    Not in our library10.1007/s00702-004-0168-161

  33. 33.

    Boyson S. J. Mcgonigle P. Molinoff P. B. (1986 ). Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6 3177–3188

    Not in our library10.1523/jneurosci.06-11-03177.1986

  34. 34.

    Bradshaw C. P. Goldweber A. Fishbein D. Greenberg M. T. (2012 ). Infusing developmental neuroscience into school-based preventive interventions: implications and future directions. J. Adolesc. Health 51 S41–S47

    Not in our library10.1016/j.jadohealth.2012.04.020

  35. 35.

    Brenhouse H. C. Sonntag K. C. Andersen S. L. (2008 ). Transient D1 dopamine receptor expression on prefrontal cortex projection neurons: relationship to enhanced motivational salience of drug cues in adolescence. J. Neurosci. 28 2375–2382

    Not in our library10.1523/jneurosci.5064-07.2008

  36. 36.

    Brown R. W. Maple A. M. Perna M. K. Sheppard A. B. Cope Z. A. Kostrzewa R. M. (2012 ). Schizophrenia and substance abuse comorbidity: nicotine addiction and the neonatal quinpirole model. Dev. Neurosci. 34 140–151

    Not in our library10.1159/000338830

  37. 37.

    Bruel-Jungerman E. Lucassen P. J. Francis F. (2011 ). Cholinergic influences on cortical development and adult neurogenesis. Behav. Brain Res. 221 379–388

    Not in our library10.1016/j.bbr.2011.01.021

  38. 38.

    Canals M. Marcellino D. Fanelli F. Ciruela F. De Benedetti P. Goldberg S. R. (2003 ). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278 46741–46749

    Not in our library10.1074/jbc.m306451200

  39. 39.

    Carpenter A. C. Saborido T. P. Stanwood G. D. (2012 ). Development of hyperactivity and anxiety responses in dopamine transporter-deficient mice. Dev. Neurosci. 34 250–257

    Not in our library10.1159/000336824

  40. 40.

    Carter C. S. Perlstein W. Ganguli R. Brar J. Mintun M. Cohen J. D. (1998 ). Functional hypofrontality and working memory dysfunction in schizophrenia. Am. J. Psychiatry 155 1285–1287

    Not in our library10.1176/ajp.155.9.1285

  41. 41.

    Cazorla M. Shegda M. Ramesh B. Harrison N. L. Kellendonk C. (2012 ). Striatal D2 receptors regulate dendritic morphology of medium spiny neurons via Kir2 channels. J. Neurosci. 32 2398–2409

    Not in our library10.1523/jneurosci.6056-11.2012

  42. 42.

    Comings D. E. Comings B. G. Muhleman D. Dietz G. Shahbahrami B. Tast D. (1991 ). The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266 1793–1800

    Not in our library10.1001/jama.1991.03470130073032

  43. 43.

    Cornew L. Roberts T. P. Blaskey L. Edgar J. C. (2012 ). Resting-state oscillatory activity in autism spectrum disorders. J. Autism Dev. Disord. 42 1884–1894

    Not in our library10.1007/s10803-011-1431-1436

  44. 44.

    Couppis M. H. Kennedy C. H. Stanwood G. D. (2008 ). Differences in aggressive behavior and in the mesocorticolimbic DA system between A/J and BALB/cJ mice. Synapse 62 715–724

    Not in our library10.1002/syn.20545

  45. 45.

    Crandall J. E. Hackett H. E. Tobet S. A. Kosofsky B. E. Bhide P. G. (2004 ). Cocaine exposure decreases GABA neuron migration from the ganglionic eminence to the cerebral cortex in embryonic mice. Cereb. Cortex 14 665–675

    Not in our library10.1093/cercor/bhh027

  46. 46.

    Crandall J. E. Mccarthy D. M. Araki K. Y. Sims J. R. Ren J.-Q. Bhide P. G. (2007 ). Dopamine receptor activation modulates GABA neuron migration from the basal forebrain to the cerebral cortex. J. Neurosci. 27 3813–3822

    Not in our library10.1523/jneurosci.5124-06.2007

  47. 47.

    Critchlow H. M. Maycox P. R. Skepper J. N. Krylova O. (2006 ). Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol. Cell. Neurosci. 32 356–365

    Not in our library10.1016/j.mcn.2006.05.007

  48. 48.

    Curley A. A. Arion D. Volk D. W. Asafu-Adjei J. K. Sampson A. R. Fish K. N. (2011 ). Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 168 921–929

    Not in our library10.1176/appi.ajp.2011.11010052

  49. 49.

    de Carlos J. A. Lopez-Mascaraque L. Valverde F. (1996 ). Dynamics of cell migration from the lateral ganglionic eminence in the rat. J. Neurosci. 16 6146–6156

    Not in our library10.1523/jneurosci.16-19-06146.1996

  50. 50.

    de Krom M. Staal W. G. Ophoff R. A. Hendriks J. Buitelaar J. Franke B. (2009 ). A common variant in DRD3 receptor is associated with autism spectrum disorder. Biol. Psychiatry 65 625–630

    Not in our library10.1016/j.biopsych.2008.09.035

  51. 51.

    Denhardt D. T. (1999 ). “Signal transduction pathways and regulation of the mammalian cell cycle: cell type-dependent integration of external signals,” in The Molecular Basis of Cell Cycle and Growth Control ed. Stein G. S. (New York: Wiley-Liss) 225–304

    Not in our library

  52. 52.

    D’Haenen H A. Bossuyt A. (1994 ). Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol. Psychiatry 35 128–132

    Not in our library10.1016/0006-3223(94)91202-5

  53. 53.

    Di Forti M. Lappin J. M. Murray R. M. (2007 ). Risk factors for schizophrenia–all roads lead to dopamine. Eur. Neuropsychopharmacol. 17(Suppl. 2) S101–S107

    Not in our library10.1016/j.euroneuro.2007.02.005

  54. 54.

    Duman R. S. Aghajanian G. K. (2012 ). Synaptic dysfunction in depression: potential therapeutic targets. Science 338 68–72

    Not in our library10.1126/science.1222939

  55. 55.

    Dwyer J. B. Mcquown S. C. Leslie F. M. (2009 ). The dynamic effects of nicotine on the developing brain. Pharmacol. Ther. 122 125–139

    Not in our library10.1016/j.pharmthera.2009.02.003

  56. 56.

    Egeland M. Zhang X. Millan M. J. Mocaer E. Svenningsson P. (2012 ). Pharmacological or genetic blockade of the dopamine D3 receptor increases cell proliferation in the hippocampus of adult mice. J. Neurochem. 123 811–823

    Not in our library10.1111/jnc.12011

  57. 57.

    Fasano C. Bourque M. J. Lapointe G. Leo D. Thibault D. Haber M. (2013 ). Dopamine facilitates dendritic spine formation by cultured striatal medium spiny neurons through both D1 and D2 dopamine receptors. Neuropharmacology 67 432–443

    Not in our library10.1016/j.neuropharm.2012.11.030

  58. 58.

    Finlay J. M. (2001 ). Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophr. Bull. 27 431–442

    Not in our library10.1093/oxfordjournals.schbul.a006885

  59. 59.

    Frederick A. L. Stanwood G. D. (2009 ). Drugs, biogenic amine targets and the developing brain. Dev. Neurosci. 31 7–22

    Not in our library10.1159/000207490

  60. 60.

    Fuxe K. Ferre S. Genedani S. Franco R. Agnati L. F. (2007 ). Adenosine receptor-dopamine receptor interactions in the basal ganglia and their relevance for brain function. Physiol. Behav. 92 210–217

    Not in our library10.1016/j.physbeh.2007.05.034

  61. 61.

    Gadow K. D. Devincent C. J. Olvet D. M. Pisarevskaya V. Hatchwell E. (2010 ). Association of DRD4 polymorphism with severity of oppositional defiant disorder, separation anxiety disorder and repetitive behaviors in children with autism spectrum disorder. Eur. J. Neurosci. 32 1058–1065

    Not in our library10.1111/j.1460-9568.2010.07382.x

  62. 62.

    Garey L. (2010 ). When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits. J. Anat. 217 324–333

    Not in our library10.1111/j.1469-7580.2010.01231.x

  63. 63.

    Garner C. C. Zhai R. G. Gundelfinger E. D. Ziv N. E. (2002 ). Molecular mechanisms of CNS synaptogenesis. Trends Neurosci. 25 243–250

    Not in our library10.1016/s0166-2236(02)02152-5

  64. 64.

    Gaspar P. Berger B. Febvret A. Vigny A. Henry J. P. (1989 ). Catecholamine innervation of the human cerebral cortex as revealed by comparative immunohistochemistry of tyrosine hydroxylase and dopamine-beta-hydroxylase. J. Comp. Neurol. 279 249–271

    Not in our library10.1002/cne.902790208

  65. 65.

    Gertler T. S. Chan C. S. Surmeier D. J. (2008 ). Dichotomous anatomical properties of adult striatal medium spiny neurons. J. Neurosci. 28 10814–10824

    Not in our library10.1523/jneurosci.2660-08.2008

  66. 66.

    Glantz L. A. Lewis D. A. (1997 ). Reduction of synaptophysin immunoreactivity in the prefrontal cortex of subjects with schizophrenia: regional and diagnostic specificity. Arch. Gen. Psychiatry 54 660–669

    Not in our library10.1001/archpsyc.1997.01830190088009

  67. 67.

    Glantz L. A. Lewis D. A. (2000 ). Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch. Gen. Psychiatry 57 65–73

    Not in our library10.1001/archpsyc.57.1.65

  68. 68.

    Glausier J. R. Lewis D. A. (2013 ). Dendritic spine pathology in schizophrenia. Neuroscience 251 90–107

    Not in our library10.1016/j.neuroscience.2012.04.044

  69. 69.

    Goldman-Rakic P. Castner S. Svensson T. Siever L. Williams G. (2004 ). Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 174 3–16

    Not in our library10.1007/s00213-004-1793-y

  70. 70.

    Gong S. Zheng C. Doughty M. L. Losos K. Didkovsky N. Schambra U. B. (2003 ). A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 917–925

    Not in our library10.1038/nature02033

  71. 71.

    Greengard P. Allen P. B. Nairn A. C. (1999 ). Beyond the dopamine receptor: the DARPP-32/protein phosphatase-1 cascade. Neuron 23 435–447

    Not in our library10.1016/s0896-6273(00)80798-9

  72. 72.

    Gurevich E. V. Joyce J. N. (2000 ). Dopamine D(3) receptor is selectively and transiently expressed in the developing whisker barrel cortex of the rat. J. Comp. Neurol. 420 35–51

    Not in our library10.1002/(sici)1096-9861(20000424)420:1<35::aid-cne3>3.0.co;2-k

  73. 73.

    Gurevich E. V. Robertson R. T. Joyce J. N. (2001 ). Thalamo-cortical afferents control transient expression of the dopamine D(3) receptor in the rat somatosensory cortex. Cereb. Cortex 11 691–701

    Not in our library10.1093/cercor/11.8.691

  74. 74.

    Haas K. (2006 ). “Role of synaptogenesis in morphologic stabilization of developing dendrites,” in Molecular Mechanisms of Synaptogenesis eds Dityatev A. El-Husseini A. (USA: Springer) 297–309

    Not in our library

  75. 75.

    Hamilton L. R. Czoty P. W. Nader M. A. (2011 ). Behavioral characterization of adult male and female rhesus monkeys exposed to cocaine throughout gestation. Psychopharmacology (Berl.) 213 799–808

    Not in our library10.1007/s00213-010-2038-x

  76. 76.

    Han X. Li N. Xue X. Shao F. Wang W. (2012 ). Early social isolation disrupts latent inhibition and increases dopamine D2 receptor expression in the medial prefrontal cortex and nucleus accumbens of adult rats. Brain Res. 1447 38–43

    Not in our library10.1016/j.brainres.2012.01.058

  77. 77.

    Hansen D. V. Lui J. H. Flandin P. Yoshikawa K. Rubenstein J. L. Alvarez-Buylla A. (2013 ). Non-epithelial stem cells and cortical interneuron production in the human ganglionic eminences. Nat. Neurosci. 16 1576–1587

    Not in our library10.1038/nn.3541

  78. 78.

    Hansson S. R. Mezey E. Hoffman B. J. (1998 ). Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience 83 1185–1201

    Not in our library10.1016/s0306-4522(97)00444-2

  79. 79.

    Harada M. Taki M. M. Nose A. Kubo H. Mori K. Nishitani H. (2011 ). Non-invasive evaluation of the GABAergic/glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J. Autism Dev. Disord. 41 447–454

    Not in our library10.1007/s10803-010-1065-1060

  80. 80.

    Hattori T. McGeer P. L. (1973 ). Synaptogenesis in the corpus striatum of infant rat. Exp. Neurol. 38 70–79

    Not in our library10.1016/0014-4886(73)90008-3

  81. 81.

    Herlenius E. Lagercrantz H. (2001 ). Neurotransmitters and neuromodulators during early human development. Early Hum. Dev. 65 21–37

    Not in our library10.1016/s0378-3782(01)00189-x

  82. 82.

    Herve D. (2011 ). Identification of a specific assembly of the g protein golf as a critical and regulated module of dopamine and adenosine-activated cAMP pathways in the striatum. Front. Neuroanat. 5:48

    Not in our library10.3389/fnana.2011.00048

  83. 83.

    Herve D. Levi-Strauss M. Marey-Semper I. Verney C. Tassin J. P. Glowinski J. (1993 ). G(olf) and Gs in rat basal ganglia: possible involvement of G(olf) in the coupling of dopamine D1 receptor with adenylyl cyclase. J. Neurosci. 13 2237–2248

    Not in our library10.1523/jneurosci.13-05-02237.1993

  84. 84.

    Hettinger J. A. Liu X. Hudson M. L. Lee A. Cohen I. L. Michaelis R. C. (2012 ). DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families. Behav. Brain Funct. 8 19

    Not in our library10.1186/1744-9081-8-19

  85. 85.

    Hettinger J. A. Liu X. Schwartz C. E. Michaelis R. C. Holden J. J. (2008 ). A DRD1 haplotype is associated with risk for autism spectrum disorders in male-only affected sib-pair families. Am. J. Med. Genet. B Neuropsychiatry Genet. 147B 628–636

    Not in our library10.1002/ajmg.b.30655

  86. 86.

    Honer W. G. Falkai P. Chen C. Arango V. Mann J. J. Dwork A. J. (1999 ). Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 91 1247–1255

    Not in our library10.1016/s0306-4522(98)00679-4

  87. 87.

    Ingham C. A. Hood S. H. Arbuthnott G. W. (1989 ). Spine density on neostriatal neurones changes with 6-hydroxydopamine lesions and with age. Brain Res. 503 334–338

    Not in our library10.1016/0006-8993(89)91686-7

  88. 88.

    Ingham C. A. Hood S. H. Arbuthnott G. W. (1991 ). A light and electron microscopical study of enkephalin-immunoreactive structures in the rat neostriatum after removal of the nigrostriatal dopaminergic pathway. Neuroscience 42 715–730

    Not in our library10.1016/0306-4522(91)90040-u

  89. 89.

    Ingham C. A. Hood S. H. Maldegem B. Weenink A. Arbuthnott G. W. (1993 ). Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway. Exp. Brain Res. 93 17–27

    Not in our library10.1007/bf00227776

  90. 90.

    Iwakura Y. Nawa H. Sora I. Chao M. V. (2008 ). Dopamine D1 receptor-induced signaling through TrkB receptors in striatal neurons. J. Biol. Chem. 283 15799–15806

    Not in our library10.1074/jbc.m801553200

  91. 91.

    Jia J. -M. Zhao J. Hu Z. Lindberg D. Li Z. (2013 ). Age-dependent regulation of synaptic connections by dopamine D2 receptors. Nat. Neurosci. 16 1627–1636

    Not in our library10.1038/nn.3542

  92. 92.

    Jonas R. K. Montojo C. A. Bearden C. E. (2013 ). The 22q11.2 deletion syndrome as a window into complex neuropsychiatric disorders over the lifespan. Biol. Psychiatry [Epub ahead of print]

    Not in our library10.1016/j.biopsych.2013.07.019

  93. 93.

    Jones L. B. Stanwood G. D. Reinoso B. S. Washington R. A. Wang H.-Y. Friedman E. (2000 ). In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J. Neurosci. 20 4606–4614

    Not in our library10.1523/jneurosci.20-12-04606.2000

  94. 94.

    Jung A. B. Bennett J. P. Jr (1996 ). Development of striatal dopaminergic function. I. Pre- and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors. Brain Res. Dev. Brain Res. 94 109–120

    Not in our library10.1016/0165-3806(96)00033-8

  95. 95.

    Kalivas P. W. Volkow N. Seamans J. (2005 ). Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45 647–650

    Not in our library10.1016/j.neuron.2005.02.005

  96. 96.

    Kalsbeek A. Matthijssen M. A. H Uylings H. B. M. (1989 ). Morphometric analysis of prefrontal cortical development following neonatal lesioning of the dopaminergic mesocortical projection. Exp. Brain Res. 78 279–289

    Not in our library10.1007/bf00228899

  97. 97.

    Kalsbeek A. Voorn P. Buijs R. M. Pool C. W. Uylings H. B. (1988 ). Development of the dopaminergic innervation in the prefrontal cortex of the rat. J. Comp. Neurol. 269 58–72

    Not in our library10.1002/cne.902690105

  98. 98.

    Karam C. S. Ballon J. S. Bivens N. M. Freyberg Z. Girgis R. R. Lizardi-Ortiz J. E. (2010 ). Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends Pharmacol. Sci. 31 381–390

    Not in our library10.1016/j.tips.2010.05.004

  99. 99.

    Karege F. Meary A. Perroud N. Jamain S. Leboyer M. Ballmann E. (2012 ). Genetic overlap between schizophrenia and bipolar disorder: a study with AKT1 gene variants and clinical phenotypes. Schizophr. Res. 135 8–14

    Not in our library10.1016/j.schres.2011.12.015

  100. 100.

    Kaufmann W. E. Moser H. W. (2000 ). Dendritic anomalies in disorders associated with mental retardation. Cereb. Cortex 10 981–991

    Not in our library10.1093/cercor/10.10.981

  101. 101.

    Kellendonk C. Simpson E. H. Polan H. J. Malleret G. Vronskaya S. Winiger V. (2006 ). Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49 603–615

    Not in our library10.1016/j.neuron.2006.01.023

  102. 102.

    Kern C. H. Stanwood G. D. Smith D. R. (2010 ). Preweaning manganese exposure causes hyperactivity, disinhibition, and spatial learning and memory deficits associated with altered dopamine receptor and transporter levels. Synapse 64 363–378

    Not in our library10.1002/syn.20736

  103. 103.

    Kim Y. Wang W. Z. Comte I. Pastrana E. Tran P. B. Brown J. (2010 ). Dopamine stimulation of postnatal murine subventricular zone neurogenesis via the D3 receptor. J. Neurochem. 114 750–760

    Not in our library10.1111/j.1471-4159.2010.06799.x

  104. 104.

    Krasnova I. N. Betts E. S. Dada A. Jefferson A. Ladenheim B. Becker K. G. (2007 ). Neonatal dopamine depletion induces changes in morphogenesis and gene expression in the developing cortex. Neurotox. Res. 11 107–130

    Not in our library10.1007/bf03033390

  105. 105.

    Langen M. Leemans A. Johnston P. Ecker C. Daly E. Murphy C. M. (2012 ). Front-striatal circuitry and inhibitory control in autism: findings from diffusion tensor imaging tractography. Cortex 48 183–193

    Not in our library10.1016/j.cortex.2011.05.018

  106. 106.

    Lao C. L. Lu C. S. Chen J. C. (2013 ). Dopamine D(3) receptor activation promotes neural stem/progenitor cell proliferation through AKT and ERK1/2 pathways and expands type-B and -C cells in adult subventricular zone. Glia 61 475–489

    Not in our library10.1002/glia.22449

  107. 107.

    Le Moine C. Bloch B. (1995 ). D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355 418–426

    Not in our library10.1002/cne.903550308

  108. 108.

    Le Moine C. Gaspar P. (1998 ). Subpopulations of cortical GABAergic interneurons differ by their expression of D1 and D2 dopamine receptor subtypes. Mol. Brain Res. 58 231–236

    Not in our library10.1016/s0169-328x(98)00118-1

  109. 109.

    Lee F. J. Xue S. Pei L. Vukusic B. Chery N. Wang Y. (2002 ). Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111 219–230

    Not in our library10.1016/s0092-8674(02)00962-5

  110. 110.

    Leppanen J. M. (2006 ). Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr. Opin. Psychiatry 19 34–39

    Not in our library10.1097/01.yco.0000191500.46411.00

  111. 111.

    Letinic K. Zoncu R. Rakic P. (2002 ). Origin of GABAergic neurons in the human neocortex. Nature 417 645–649

    Not in our library10.1038/nature00779

  112. 112.

    Lewis D. A. Levitt P. (2002 ). Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci. 25 409–432

    Not in our library10.1146/annurev.neuro.25.112701.142754

  113. 113.

    Lewis P. D. Patel A. J. Bendek G. Balazs R. (1977 ). Effect of reserpine on cell proliferation in the developing rat brain: a quantivative histological study. Brain Res. 129 299–308

    Not in our library10.1016/0006-8993(77)90009-9

  114. 114.

    Li F. Ohtani A. Senzaki K. Shiga T. (2013 ). Receptor-dependent regulation of dendrite formation of noradrenaline and dopamine in non-gabaergic cerebral cortical neurons. Dev. Neurobiol. 73 370–383

    Not in our library10.1002/dneu.22065

  115. 115.

    Li X. Rosborough K. M. Friedman A. B. Zhu W. Roth K. A. (2007 ). Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int. J. Neuropsychopharmacol. 10 7–19

    Not in our library10.1017/s1461145706006547

  116. 116.

    Lipton S. A. Frosch M. P. Phillips M. D. Tauck D. L. Aizenman E. (1988 ). Nicotinic antagonists enhance process outgrowth by rat retinal ganglion cells in culture. Science 239 1293–1296

    Not in our library10.1126/science.3344435

  117. 117.

    Liu J. Lester B. M. Neyzi N. Sheinkopf S. J. Gracia L. Kekatpure M. (2013 ). Regional brain morphometry and impulsivity in adolescents following prenatal exposure to cocaine and tobacco. JAMA Pediatr. 167 348–354

    Not in our library10.1001/jamapediatrics.2013.550

  118. 118.

    Liu W. S. Pesold C. Rodriguez M. A. Carboni G. Auta J. Lacor P. (2001 ). Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc. Natl. Acad. Sci. U.S.A. 98 3477–3482

    Not in our library10.1073/pnas.051614698

  119. 119.

    Logue S. F. Grauer S. M. Paulsen J. Graf R. Taylor N. Sung M. A. (2009 ). The orphan GPCR, GPR88, modulates function of the striatal dopamine system: a possible therapeutic target for psychiatric disorders? Mol. Cell. Neurosci. 42 438–447

    Not in our library10.1016/j.mcn.2009.09.007

  120. 120.

    Lotto B. Upton L. Price D. J. Gaspar P. (1999 ). Serotonin receptor activation enhances neurite outgrowth of thalamic neurones in rodents. Neurosci. Lett. 269 87–90

    Not in our library10.1016/s0304-3940(99)00422-x

  121. 121.

    Lovestone S. Killick R. Di Forti M. Murray R. (2007 ). Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 30 142–149

    Not in our library10.1016/j.tins.2007.02.002

  122. 122.

    Lu H. Lim B. Poo M.-M. (2009 ). Cocaine exposure in utero alters synaptic plasticity in the medial prefrontal cortex of postnatal rats. J. Neurosci. 29 12664–12674

    Not in our library10.1523/jneurosci.1984-09.2009

  123. 123.

    Ma T. Wang C. Wang L. Zhou X. Tian M. Zhang Q. (2013 ). Subcortical origins of human and monkey neocortical interneurons. Nat. Neurosci. 16 1588–1597

    Not in our library10.1038/nn.3536

  124. 124.

    Marley A. Choy R. W Von Zastrow M. (2013 ). GPR88 reveals a discrete function of primary cilia as selective insulators of GPCR cross-talk. PLoS ONE 8:e70857

    Not in our library10.1371/journal.pone.0070857

  125. 125.

    McAllister A. K. (2000 ). Cellular and molecular mechanisms of dendrite growth. Cereb. Cortex 10 963–973

    Not in our library10.1093/cercor/10.10.963

  126. 126.

    McCarthy D. Lueras P. Bhide P. G. (2007 ). Elevated dopamine levels during gestation produce region-specific decreases in neurogenesis and subtle deficits in neuronal numbers. Brain Res. 1182 11–25

    Not in our library10.1016/j.brainres.2007.08.088

  127. 127.

    McCarthy D. M. Zhang X. Darnell S. B. Sangrey G. R. Yanagawa Y. Sadri-Vakili G. (2011 ). Cocaine alters BDNF expression and neuronal migration in the embryonic mouse forebrain. J. Neurosci. 31 13400–13411

    Not in our library10.1523/jneurosci.2944-11.2011

  128. 128.

    McGlashan T. H. Hoffman R. E. (2000 ). SChizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch. Gen. Psychiatry 57 637–648

    Not in our library10.1001/archpsyc.57.7.637

  129. 129.

    Meador-Woodruff J. H. Damask S. P. Wang J. Haroutunian V. Davis K. L. Watson S. J. (1996 ). Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15 17–29

    Not in our library10.1016/0893-133x(95)00150-c

  130. 130.

    Medalia A. Lim R. (2004 ). Treatment of cognitive dysfunction in psychiatric disorders. J. Psychiatr. Pract. 10 17–25

    Not in our library10.1097/00131746-200401000-00003

  131. 131.

    Millar J. K. Christie S. Anderson S. Lawson D. Hsiao-Wei Loh D. Devon R. S. (2001 ). Genomic structure and localisation within a linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol. Psychiatry 6 173–178

    Not in our library10.1038/sj.mp.4000784

  132. 132.

    Missale C. Nash S. R. Robinson S. W. Jaber M. Caron M. G. (1998 ). Dopamine receptors: from structure to function. Physiol. Rev. 78 189–225

    Not in our library10.1152/physrev.1998.78.1.189

  133. 133.

    Muly E. C. 3rd Szigeti K. Goldman-Rakic P. S. (1998 ). D1 receptor in interneurons of macaque prefrontal cortex: distribution and subcellular localization. J. Neurosci. 18 10553–10565

    Not in our library10.1523/jneurosci.18-24-10553.1998

  134. 134.

    Murphy B. L. Arnsten A. F. Goldman-Rakic P. S. Roth R. H. (1996 ). Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc. Natl. Acad. Sci. U.S.A. 93 1325–1329

    Not in our library10.1073/pnas.93.3.1325

  135. 135.

    Nai Q. Li S. Wang S. H. Liu J. Lee F. J. Frankland P. W. (2010 ). Uncoupling the D1-N-methyl-D-aspartate (NMDA) receptor complex promotes NMDA-dependent long-term potentiation and working memory. Biol. Psychiatry 67 246–254

    Not in our library10.1016/j.biopsych.2009.08.011

  136. 136.

    Nair V. D. Mishra R. K. (1995 ). Ontogenic development of dopamine D4 receptor in rat brain. Brain Res. Dev. Brain Res. 90 180–183

    Not in our library10.1016/0165-3806(96)83499-7

  137. 137.

    Navarro G. Moreno E. Bonaventura J. Brugarolas M. Farre D. Aguinaga D. (2013 ). Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS ONE 8:e61245

    Not in our library10.1371/journal.pone.0061245

  138. 138.

    Neely M. D. Schmidt D. E. Deutch A. Y. (2007 ). Cortical regulation of dopamine depletion-induced dendritic spine loss in striatal medium spiny neurons. Neuroscience 149 457–464

    Not in our library10.1016/j.neuroscience.2007.06.044

  139. 139.

    Neisewander J. L. Lucki I. Mcgonigle P. (1991 ). Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment. Brain Res. 558 27–35

    Not in our library10.1016/0006-8993(91)90710-d

  140. 140.

    Niwa M. Kamiya A. Murai R. Kubo K. Gruber A. J. Tomita K. (2010 ). Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits. Neuron 65 480–489

    Not in our library10.1016/j.neuron.2010.01.019

  141. 141.

    Nohesara S. Ghadirivasfi M. Mostafavi S. Eskandari M. R. Ahmadkhaniha H. Thiagalingam S. (2011 ). DNA hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. J. Psychiatr. Res. 45 1432–1438

    Not in our library10.1016/j.jpsychires.2011.06.013

  142. 142.

    O’Brien M. S. Anthony J. C. (2005 ). Risk of becoming cocaine dependent: epidemiological estimates for the United States, 2000–2001. Neuropsychopharmacology 30 1006–1018

    Not in our library10.1038/sj.npp.1300681

  143. 143.

    Ohtani N. Goto T. Waeber C. Bhide P. G. (2003 ). Dopamine modulates cell cycle in the lateral ganglionic eminence. J. Neurosci. 23 2840–2850

    Not in our library10.1523/jneurosci.23-07-02840.2003

  144. 144.

    Okubo Y. Suhara T. Suzuki K. Kobayashi K. Inoue O. Terasaki O. (1997 ). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385 634–636

    Not in our library10.1038/385634a0

  145. 145.

    Olson L. Boréus L. O Seiger Å (1973 ). Histochemical demonstration and mapping of 5-hydroxytryptamine- and catecholamine-containing neuron systems in the human fetal brain. Z. Anat. Entwicklungsgesch. 139 259–282

    Not in our library10.1007/bf00519968

  146. 146.

    Onténiente B. König N. Sievers J. Jenner S. Klemm H. P. Marty R. (1980 ). Structural and biochemical changes in rat cerebral cortex after neonatal 6-hydroxydopamine administration. Anat. Embryol. 159 245–255

    Not in our library10.1007/bf00317649

  147. 147.

    Padmanabhan A. Luna B. (2013 ). Developmental imaging genetics: linking dopamine function to adolescent behavior. Brain Cogn.

    Not in our library10.1016/j.bandc.2013.09.011

  148. 148.

    Parker D. Ferreri K. Nakajima T. Lamorte V. J. Evans R. Koerber S. C. (1996 ). Phosphorylation of CREB at Ser-133 induces complex formation with CREB-binding protein via a direct mechanism. Mol. Cell. Biol. 16 694–703

    Not in our library10.1128/mcb.16.2.694

  149. 149.

    Patel A. J. Bendek G. Balazs R. Lewis P. D. (1977 ). Effect of reserpine on cell proliferation in the developing rat bran: a biochemical study. Brain Res. 129 283–297

    Not in our library10.1016/0006-8993(77)90008-7

  150. 150.

    Penzes P. Cahill M. E. Jones K. A. Vanleeuwen J. E. Woolfrey K. M. (2011 ). Dendritic spine pathology in neuropsychiatric disorders. Nat. Neurosci. 14 285–293

    Not in our library10.1038/nn.2741

  151. 151.

    Persico A. M. Di Pino G. Levitt P. (2006 ). Multiple receptors mediate the trophic effects of serotonin on ventroposterior thalamic neurons in vitro. Brain Res. 1095 17–25

    Not in our library10.1016/j.brainres.2006.04.006

  152. 152.

    Petanjek Z. Kostovic I. Esclapez M. (2009 ). Primate-specific origins and migration of cortical GABAergic neurons. Front. Neuroanat. 3:26

    Not in our library10.3389/neuro.05.026.2009

  153. 153.

    Piazza P. V. Rougé-Pont F. Deminière J. M. Kharoubi M. Le Moal M. Simon H. (1991 ). Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res. 567 169–174

    Not in our library10.1016/0006-8993(91)91452-7

  154. 154.

    Pino G. D. Moessner R. Lesch K. Lauder J. Persico A. (2004 ). Roles for serotonin in neurodevelopment: more than just neural transmission. Curr. Neuropharmacol. 2 403–417

    Not in our library10.2174/1570159043359495

  155. 155.

    Popolo M. Mccarthy D. M. Bhide P. G. (2004 ). Influence of dopamine on precursor cell proliferation and differentiation in the embryonic mouse telencephalon. Dev. Neurosci. 26 229–244

    Not in our library10.1159/000082140

  156. 156.

    Prestoz L. Jaber M. Gaillard A. (2012 ). Dopaminergic axon guidance: which makes what? Front. Cell. Neurosci. 6:32

    Not in our library10.3389/fncel.2012.00032

  157. 157.

    Pugh P. C. Berg D. K. (1994 ). Neuronal acetylcholine receptors that bind alpha-bungarotoxin mediate neurite retraction in a calcium-dependent manner. J. Neurosci. 14 889–896

    Not in our library10.1523/jneurosci.14-02-00889.1994

  158. 158.

    Radhu N. De Jesus D. R. Ravindran L. N. Zanjani A. Fitzgerald P. B. Daskalakis Z. J. (2013 ). A meta-analysis of cortical inhibition and excitability using transcranial magnetic stimulation in psychiatric disorders. Clin. Neurophysiol. 124 1309–1320

    Not in our library10.1016/j.clinph.2013.01.014

  159. 159.

    Rapoport J. L. Giedd J. N. Gogtay N. (2012 ). Neurodevelopmental model of schizophrenia: update 2012. Mol. Psychiatry 17 1228–1238

    Not in our library10.1038/mp.2012.23

  160. 160.

    Reinoso B. S. Undie A. S. Levitt P. (1996 ). Dopamine receptors mediate differential morphological effects on cerebral cortical neurons in vitro. J. Neurosci. Res. 43 439–453

    Not in our library10.1002/(sici)1097-4547(19960215)43:4<439::aid-jnr5>3.0.co;2-g

  161. 161.

    Roeper J. (2013 ). Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 36 336–342

    Not in our library10.1016/j.tins.2013.03.003

  162. 162.

    Rosenberg D. R. Lewis D. A. (1995 ). Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: a tyrosine hydroxylase immunohistochemical analysis. J. Comp. Neurol. 358 383–400

    Not in our library10.1002/cne.903580306

  163. 163.

    Roussotte F. Soderberg L. Warner T. Narr K. Lebel C. Behnke M. (2012 ). Adolescents with prenatal cocaine exposure show subtle alterations in striatal surface morphology and frontal cortical volumes. J. Neurodev. Disord. 4 22

    Not in our library10.1186/1866-1955-4-22

  164. 164.

    Ruediger T. Bolz J. (2007 ). Neurotransmitters and the development of neuronal circuits. Adv. Exp. Med. Biol. 621 104–115

    Not in our library10.1007/978-0-387-76715-4_8

  165. 165.

    Sanchez C. Diaz-Nido J. Avila J. (2000 ). Phosphorylation of microtubule-associated protein 2 (MAP2) and its relevance for the regulation of the neuronal cytoskeleton function. Progr. Neurobiol. 61 133–168

    Not in our library10.1016/s0301-0082(99)00046-5

  166. 166.

    Santana N. Mengod G. Artigas F. (2009 ). Quantitative analysis of the expression of dopamine D1 and D2 receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb. Cortex 19 849–860

    Not in our library10.1093/cercor/bhn134

  167. 167.

    Schambra U. B. Duncan G. E. Breese G. R. Fornaretto M. G. Caron M. G. Fremeau R. T. Jr (1994 ). Ontogeny of D1A and D2 dopamine receptor subtypes in rat brain using in situ hybridization and receptor binding. Neuroscience 62 65–85

    Not in our library10.1016/0306-4522(94)90315-8

  168. 168.

    Schmidt U. Beyer C. Oestreicher A. B. Reisert I. Schilling K. Pilgrim C. (1996 ). Activation of dopaminergic D1 receptors promotes morphogenesis of developing striatal neurons. Neuroscience 74 453–460

    Not in our library10.1016/0306-4522(96)00201-1

  169. 169.

    Schmidt U. Pilgrim C. Beyer C. (1998 ). Differentiative effects of dopamine on striatal neurons involve stimulation of the cAMP/PKA pathway. Mol. Cell. Neurosci. 11 9–18

    Not in our library10.1006/mcne.1998.0668

  170. 170.

    Selemon L. D. Friedman H. R. (2013 ). Motor stereotypies and cognitive perseveration in non-human primates exposed to early gestational irradiation. Neuroscience 248C 213–224

    Not in our library10.1016/j.neuroscience.2013.06.006

  171. 171.
    Synapse-specific contributions in the cortical pathology of schizophrenia · 2013
    Not checked
  172. 172.

    Shah P. J. Ogilvie A. D. Goodwin G. M. Ebmeier K. P. (1997 ). Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol. Med. 27 1247–1256

    Not in our library10.1017/s0033291797005382

  173. 173.

    Sharp S. I. Mcquillin A. Gurling H. M. (2009 ). Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology 57 590–600

    Not in our library10.1016/j.neuropharm.2009.08.011

  174. 174.

    Sheaff R. Roberts J. (1998 ). Regulation of G1 phase. Results Probl. Cell Differ. 22 1–34

    Not in our library10.1007/978-3-540-69686-5_1

  175. 175.

    Shen J. Zhang L. Song W. L. Meng T. Wang X. Chen L. (2013 ). Design, synthesis and biological evaluation of bivalent ligands against A1-D1 receptor heteromers. Acta Pharma. Sin. 34 441–452

    Not in our library10.1038/aps.2012.151

  176. 176.

    Sherren N. Pappas B. A. (2005 ). Selective acetylcholine and dopamine lesions in neonatal rats produce distinct patterns of cortical dendritic atrophy in adulthood. Neuroscience 136 445–456

    Not in our library10.1016/j.neuroscience.2005.08.053

  177. 177.

    Shuen J. A. Chen M. Gloss B. Calakos N. (2008 ). Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J. Neurosci. 28 2681–2685

    Not in our library10.1523/jneurosci.5492-07.2008

  178. 178.

    Sigala S. Zoli M. Palazzolo F. Faccoli S. Zanardi A. Mercuri N. B. (2007 ). Selective disarrangement of the rostral telencephalic cholinergic system in heterozygous reeler mice. Neuroscience 144 834–844

    Not in our library10.1016/j.neuroscience.2006.10.013

  179. 179.

    Sillivan S. E. (2011 ). Dopamine Receptor Stimulation Regulates Expression of Developmental Genes and Disrupts Netrin-1-Mediated Axon Guidance. Ph.D thesis, Vanderbilt University Nashville

    Not in our library

  180. 180.

    Sillivan S. E. Konradi C. (2011 ). Expression and function of dopamine receptors in the developing medial frontal cortex and striatum of the rat. Neuroscience 199 501–514

    Not in our library10.1016/j.neuroscience.2011.10.004

  181. 181.

    Simpson E. H. Kellendonk C. Kandel E. (2010 ). A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia. Neuron 65 585–596

    Not in our library10.1016/j.neuron.2010.02.014

  182. 182.

    Small D. H. Reed G. Whitefield B. Nurcombe V. (1995 ). Cholinergic regulation of neurite outgrowth from isolated chick sympathetic neurons in culture. J. Neurosci. 15 144–151

    Not in our library10.1523/jneurosci.15-01-00144.1995

  183. 183.

    Smiley J. F. Williams S. M. Szigeti K. Goldman-Rakic P. S. (1992 ). Light and electron microscopic characterization of dopamine-immunoreactive axons in human cerebral cortex. J. Comp. Neurol. 321 325–335

    Not in our library10.1002/cne.903210302

  184. 184.

    Song Z. M. Undie A. S. Koh P. O. Fang Y. Y. Zhang L. Dracheva S. (2002 ). D1 dopamine receptor regulation of microtubule-associated protein-2 phosphorylation in developing cerebral cortical neurons. J. Neurosci. 22 6092–6105

    Not in our library10.1523/jneurosci.22-14-06092.2002

  185. 185.

    Spencer G. E. Klumperman J. Syed N. I. (1998 ). Neurotransmitters and neurodevelopment. Role of dopamine in neurite outgrowth, target selection and specific synapse formation. Perspect. Dev. Neurobiol. 5 451–467

    Not in our library

  186. 186.

    Speranza L. Chambery A. Di Domenico M. Crispino M. Severino V. Volpicelli F. (2013 ). The serotonin receptor 7 promotes neurite outgrowth via ERK and Cdk5 signaling pathways. Neuropharmacology 67 155–167

    Not in our library10.1016/j.neuropharm.2012.10.026

  187. 187.

    Spronsen M. Hoogenraad C. (2010 ). Synapse pathology in psychiatric and neurologic disease. Curr. Neurol. Neurosci. Rep. 10 207–214

    Not in our library10.1007/s11910-010-0104-108

  188. 188.

    Staal W. G. De Krom M De Jonge M. V. (2012 ). Brief report: the dopamine-3-receptor gene (DRD3) is associated with specific repetitive behavior in autism spectrum disorder (ASD). J. Autism Dev. Disord. 42 885–888

    Not in our library10.1007/s10803-011-1312-z

  189. 189.

    Stanwood G. Levitt P. (2001 ). “The effects of cocaine on the developing nervous system,” Handbook of Developmental Cognitive Neuroscience eds Nelson C. A. Luciana M. (Cambridge: MIT Press) 519–536

    Not in our library

  190. 190.

    Stanwood G. D. Levitt P. (2007 ). Prenatal exposure to cocaine produces unique developmental and long-term adaptive changes in dopamine D1 receptor activity and subcellular distribution. J. Neurosci. 27 152–157

    Not in our library10.1523/jneurosci.4591-06.2007

  191. 191.

    Stanwood G. D. Parlaman J. P. Levitt P. (2005 ). Anatomical abnormalities in dopaminoceptive regions of the cerebral cortex of dopamine D1 receptor mutant mice. J. Comp. Neurol. 487 270–282

    Not in our library10.1002/cne.20548

  192. 192.

    Stanwood G. D. Washington R. A. Levitt P. (2001a ). Identification of a sensitive period of prenatal cocaine exposure that alters the development of the anterior cingulate cortex. Cereb. Cortex 11 430–440

    Not in our library10.1093/cercor/11.5.430

  193. 193.

    Stanwood G. D. Washington R. A. Shumsky J. S. Levitt P. (2001b ). Prenatal cocaine exposure produces consistent developmental alterations in dopamine-rich regions of the cerebral cortex. Neuroscience 106 5–14

    Not in our library10.1016/s0306-4522(01)00256-1

  194. 194.

    Südhof T. (2006 ). "Synaptogenesis: when long-distance relations become intimate," in Molecular Mechanisms of Synaptogenesis eds Dityatev A. El-Husseini A. (USA: Springer) 1–9

    Not in our library

  195. 195.

    Sugahara M. Shiraishi H. (1998 ). Synaptic density of the prefrontal cortex regulated by dopamine instead of serotonin in rats. Brain Res. 814 143–156

    Not in our library10.1016/s0006-8993(98)01068-3

  196. 196.

    Surmeier D. J. Carrillo-Reid L. Bargas J. (2011 ). Dopaminergic modulation of striatal neurons, circuits, and assemblies. Neuroscience 198 3–18

    Not in our library10.1016/j.neuroscience.2011.08.051

  197. 197.

    Tajiri M. Hayata-Takano A. Seiriki K. Ogata K. Hazama K. Shintani N. (2012 ). Serotonin 5-HT(7) receptor blockade reverses behavioral abnormalities in PACAP-deficient mice and receptor activation promotes neurite extension in primary embryonic hippocampal neurons: therapeutic implications for psychiatric disorders. J. Mol. Neurosci. 48 473–481

    Not in our library10.1007/s12031-012-9861-y

  198. 198.

    Tennyson V. M. Budininkas-Schoenebeck M. Gershon P. (1982 ). Effects of chronic reserpine treatment on development of maturity of the putamen in fetal rabbits. Brain Res. Bull. 9 651–662

    Not in our library10.1016/0361-9230(82)90169-1

  199. 199.

    Thiselton D. L. Vladimirov V. I. Kuo P. H. Mcclay J. Wormley B. Fanous A. (2008 ). AKT1 is associated with schizophrenia across multiple symptom dimensions in the Irish study of high density schizophrenia families. Biol. Psychiatry 63 449–457

    Not in our library10.1016/j.biopsych.2007.06.005

  200. 200.

    Thompson B. Levitt P. Stanwood G. (2009 ). Prenatal exposure to drugs: effects on brain development and implications for policy and education. Nat. Rev. Neurosci. 10 303–312

    Not in our library10.1038/nrn2598

  201. 201.

    Todd R. D. (1992 ). Neural development is regulated by classical neurotransmitters: dopamine D2 receptor stimulation enhances neurite outgrowth. Biol. Psychiatry 31 794–807

    Not in our library10.1016/0006-3223(92)90311-m

  202. 202.

    Trakhtenberg E. F. Goldberg J. L. (2012 ). The role of serotonin in axon and dendrite growth. Int. Rev. Neurobiol. 106 105–126

    Not in our library10.1016/b978-0-12-407178-0.00005-3

  203. 203.

    Tritsch N. X. Sabatini B. L. (2012 ). Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron 76 33–50

    Not in our library10.1016/j.neuron.2012.09.023

  204. 204.

    Trowbridge S. Narboux-Neme N. Gaspar P. (2011 ). Genetic models of serotonin (5-HT) depletion: what do they tell us about the developmental role of 5-HT? Anat. Rec. (Hoboken) 294 1615–1623

    Not in our library10.1002/ar.21248

  205. 205.

    van Kesteren R. E. Spencer G. E. (2003 ). The role of neurotransmitters in neurite outgrowth and synapse formation. Rev. Neurosci. 14 217–231

    Not in our library10.1515/revneuro.2003.14.3.217

  206. 206.

    Van Waes V. Tseng K. Y. Steiner H. (2011 ). GPR88 – a putative signaling molecule predominantly expressed in the striatum: cellular localization and developmental regulation. Basal Ganglia 1 83–89

    Not in our library10.1016/j.baga.2011.04.001

  207. 207.

    Verney C. Berger B. Adrien J. Vigny A. Gay M. (1982 ). Development of the dopaminergic innervation of the rat cerebral cortex. A light microscopic immunocytochemical study using anti-tyrosine hydroxylase antibodies. Brain Res. 281 41–52

    Not in our library10.1016/0165-3806(82)90111-0

  208. 208.

    Verney C. Milosevic A. Alvarez C. Berger B. (1993 ). Immunocytochemical evidence of well-developed dopaminergic and noradrenergic innervations in the frontal cerebral cortex of human fetuses at midgestation. J. Comp. Neurol. 336 331–344

    Not in our library10.1002/cne.903360303

  209. 209.

    Verney C. Zecevic N. Nikolic B. Alvarez C. Berger B. (1991 ). Early evidence of catecholaminergic cell groups in 5- and 6-week-old human embryos using tyrosine hydroxylase and dopamine-β-hydroxylase immunocytochemistry. Neurosci. Lett. 131 121–124

    Not in our library10.1016/0304-3940(91)90351-s

  210. 210.

    Villalba R. M. Lee H. Smith Y. (2009 ). Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp. Neurol. 215 220–227

    Not in our library10.1016/j.expneurol.2008.09.025

  211. 211.

    Volkow N. D. Gur R. C. Wang G. J. Fowler J. S. Moberg P. J. Ding Y. S. (1998 ). Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am. J. Psychiatry 155 344–349

    Not in our library10.1176/ajp.155.3.344

  212. 212.

    Voorn P. Kalsbeek A. Jorritsma-Byham B. Groenewegen H. J. (1988 ). The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience 25 857–887

    Not in our library10.1016/0306-4522(88)90041-3

  213. 213.

    Wang H. D. Deutch A. Y. (2008 ). Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 33 1276–1286

    Not in our library10.1038/sj.npp.1301521

  214. 214.

    Wang H. D. Stanwood G. D. Grandy D. K. Deutch A. Y. (2009 ). Dystrophic dendrites in prefrontal cortical pyramidal cells of dopamine D1 and D2 but not D4 receptor knockout mice. Brain Res. 1300 58–64

    Not in our library10.1016/j.brainres.2009.09.008

  215. 215.

    Whitford K. L. Dijkhuizen P. Polleux F. Ghosh A. (2002 ). Molecular control of cortical dendrite development. Annu. Rev. Neurosci. 25 127–149

    Not in our library10.1146/annurev.neuro.25.112701.142932

  216. 216.

    Wonders C. P. Anderson S. A. (2006 ). The origin and specification of cortical interneurons. Nat. Rev. Neurosci. 7 687–696

    Not in our library10.1038/nrn1954

  217. 217.

    Workman A. D. Charvet C. J. Clancy B. Darlington R. B. Finlay B. L. (2013 ). Modeling transformations of neurodevelopmental sequences across mammalian species. J. Neurosci. 33 7368–7383

    Not in our library10.1523/jneurosci.5746-12.2013

  218. 218.

    Yokofujita J. Oda S. Igarashi H. Sato F. Kuroda M. (2008 ). Synaptic characteristics between cortical cells in the rat prefrontal cortex and axon terminals from the ventral tegmental area that utilize different neurotransmitters. Int. J. Neurosci. 118 1443–1459

    Not in our library10.1080/00207450701870253

  219. 219.

    Yuste R. Bonhoeffer T. (2001 ). Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu. Rev. Neurosci. 24 1071–1089

    Not in our library10.1146/annurev.neuro.24.1.1071

  220. 220.

    Yuste R. Bonhoeffer T. (2004 ). Genesis of dendritic spines: insights from ultrastructural and imaging studies. Nat. Rev. Neurosci. 5 24–34

    Not in our library10.1038/nrn1300

  221. 221.

    Zecevic N. Verney C. (1995 ). Development of the catecholamine neurons in human embryos and fetuses, with special emphasis on the innervaton of the cerebral cortex. J. Comp. Neurol. 351 509–535

    Not in our library10.1002/cne.903510404

  222. 222.

    Zhang L. Bai J. Undie A. S. Bergson C. Lidow M. S. (2005 ). D1 dopamine receptor regulation of the levels of the cell-cycle-controlling proteins, cyclin D, P27 and Raf-1, in cerebral cortical precursor cells is mediated through cAMP-independent pathways. Cereb. Cortex 15 74–84

    Not in our library10.1093/cercor/bhh110

  223. 223.

    Zhang W. Benson D. L. (2000 ). Development and molecular organization of dendritic spines and their synapses. Hippocampus 10 512–526

    Not in our library10.1002/1098-1063(2000)10:5<512::aid-hipo2>3.0.co;2-m

  224. 224.
    Altered neurocircuitry in the dopamine transporter knockout mouse brain. · 2010
    Not checked
  225. 225.

    Zuckerman L. Rehavi M. Nachman R. Weiner I. (2003 ). Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia. Neuropsychopharmacology 28 1778–1789

    Not in our library10.1038/sj.npp.1300248

Cited by papers we hold 3

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.